123 Potential Immunological Triggers for Central Disorders of Hypersomnolence Supplementary Table 2: Continued. Variable Narcolepsy type 1 (N = 176) Narcolepsy type 2 or idiopathic hypersomnia (N = 44) Odds ratio (95% CI) Effect size Corrected p-value Infections & influenza vaccinations N Percentage of N N Percentage of N Other respiratory infection prevalence 136 5.9% 28 25.0% 0.19 (0.060.57) 0.2495 0.0077 Other non-respiratory infection prevalence 136 7.4% 28 10.7% 0.66 (0.17-2.58) 0.0468 0.6606# Proportion of flu of all infections 37 24.3% 17 5.9% 5.14 (0.6044.39) 0.2205 0.2642# Proportion of EBV of all infections 37 27.0% 17 35.3% 0.68 (0.202.33) 0.0841 0.6606 Proportion of other respiratory infections of all infections 37 21.6% 17 41.2% 0.39 (0.11-1.37) 0.2028 0.2642 Proportion of non-respiratory infections of all infections 37 27.0% 17 17.6% 1.73 (0.41-7.32) 0.1019 0.6606# Rapid onset after any infection 37 78.4% 17 47.1% 4.08 (1.1913.99) 0.3132 0.0544 Rapid onset after flu infection 9 100.0% 1 0.0% - 1.0000 0.2200# Rapid onset after EBV infection 10 70.0% 6 66.7% 1.17 (0.13-10.22) 0.0348 1.0000# Rapid onset after another respiratory infection 8 87.5% 7 57.1% 5.25 (0.4068.95) 0.3425 0.4432 Rapid onset after another nonrespiratory infection 10 60.0% 3 0.0% - 0.5071 0.3254# 4
RkJQdWJsaXNoZXIy MjY0ODMw